"Whether it's this year or next year, the odds of another economic downturn are high — and growing," Warren wrote.Politicsread more
The agreement between the White House and congressional Democrats would raise the debt ceiling for two years and permanently end the sequester.Politicsread more
The Iranian Intelligence Ministry held a briefing on Monday where they announced the alleged spies were Iranian citizens but trained by the CIA.World Newsread more
Microsoft and OpenAI announced a new partnership to build artificial general intelligence to tackle more complex tasks than current AI.Technologyread more
Two traders say Boeing's on the path to recovery.Trading Nationread more
Documents leaked to The Washington Post revealed that Huawei secretly worked with the North Korean government on its wireless network.Technologyread more
Equifax will pay at least $575 million, and potentially as much as $700 million, to settle allegations over its massive over 2017 data breach, U.S. regulators said in a...Technologyread more
CNBC's Mike Santoli breaks down the aggressive buying of "sure things" and shunning of cyclical and policy risk.Trading Nationread more
Facebook has seen an increase in the median number of comments, likes and ads clicked by users on the service from January to July, according to Audience Insights, a Facebook...Technologyread more
For investors hoping rate cuts would push the market higher, Goldman Sachs said stocks can't really go anywhere from here.Marketsread more
Here are the biggest calls on Wall Street on MondayInvestingread more
Self-reflection can lead to some cold, hard truths — at least, apparently, when it comes to biotech stock investing.
A new analysis from Cowen Research’s biotech team finds that investors would be better off ignoring — or even doing the exact opposite of — the advice of equity analysts. The worse a stock’s rating, the better its performance, on average, in the following year, the report showed.
“We have analyzed the value of sell-side ratings, and whether following them is associated with investment returns,” Cowen’s analysts wrote in their report Monday. “Unfortunately (for our job security and sense of self-worth), we find that over the last four years there was an overall inverse correlation between sell-side ratings and rating changes and the performance of biotechnology stocks.”
Each time a stock's rating was cut a notch, to a hold from a buy for example, it correlated with a 22 percent increase in price, the report said. The bigger the swing in the rating, the less the sell-side analyst's opinion mattered. The larger the jump toward a strong buy, the worse the stock performed, and vice versa when a company was downgraded to a strong sell, Cowen found.
“These data suggest that sell-side ratings are on average contra-indicators, or at best not useful, in predicting biotech stock performance,” the Cowen team wrote. “We conclude that a non-consensus investment strategy that goes against the consensus sell-side opinion could generate superior returns.”
You have to appreciate their honesty.
Cowen’s analysis comes at a time, the team pointed out, when the way investors use and compensate sell-side analysts is changing. They noted institutional investors are evaluating how they use sell-side services and how much value they provide.
It also comes as the mood among investors in biotech, specifically, “is not particularly rosy,” the team said.
“Many struggle to generate returns, gain assets and beat their benchmarks,” Cowen’s analysts wrote, despite the Nasdaq Biotechnology Index’s 450 percent return since 2009.
They looked at 30 companies in the Nasdaq Biotechnology Index that were continuously rated by at least 10 analysts during the period reviewed and compared the stocks' performance from 2015 through June 15 to their sell-side recommendations at the end of the previous year.
Cowen posited three potential explanations for the poor performance: that stock ratings are reactionary, rather than predictive; that “stock picking is not job #1,” and that “management access, collecting data points, maintaining models, and talking with investors take up time and distract from determining ratings,” and, finally, that stock ratings reflect investor consensus, which typically underperforms.
Health-care investor Les Funtleyder, a portfolio manager at E Squared Capital Management and a former sell-side analyst, said he wasn’t surprised by the findings. He also said it’s likely the phenomenon isn’t limited to biotech.
“The sell-side across all industries has had difficulties getting things right per almost all academic research,” Funtleyder said. “Among other things they tend to have positive bias because they are selling.”
What’s unique about health care, though, is that it tends to be more complicated than other industries, Funtleyder noted. So those who aren’t specialists in the space may rely a bit more on analysts.
And that, according to Cowen’s report, may not be such a good idea.